RT Journal Article
SR Electronic
T1 Dynamics and significance of the antibody response to SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.18.20155374
DO 10.1101/2020.07.18.20155374
A1 Anita S. Iyer
A1 Forrest K. Jones
A1 Ariana Nodoushani
A1 Meagan Kelly
A1 Margaret Becker
A1 Damien Slater
A1 Rachel Mills
A1 Erica Teng
A1 Mohammad Kamruzzaman
A1 Wilfredo F. Garcia-Beltran
A1 Michael Astudillo
A1 Diane Yang
A1 Tyler E. Miller
A1 Elizabeth Oliver
A1 Stephanie Fischinger
A1 Caroline Atyeo
A1 A. John Iafrate
A1 Stephen B. Calderwood
A1 Stephen A. Lauer
A1 Jingyou Yu
A1 Zhenfeng Li
A1 Jared Feldman
A1 Blake M. Hauser
A1 Timothy M. Caradonna
A1 John A. Branda
A1 Sarah E. Turbett
A1 Regina C. LaRocque
A1 Guillaume Mellon
A1 Dan H. Barouch
A1 Aaron G. Schmidt
A1 Andrew S. Azman
A1 Galit Alter
A1 Edward T Ryan
A1 Jason B. Harris
A1 Richelle C. Charles
YR 2020
UL http://medrxiv.org/content/early/2020/07/20/2020.07.18.20155374.abstract
AB BACKGROUND Characterizing the humoral immune response to SARS-CoV-2 and developing accurate serologic assays are needed for diagnostic purposes and estimating population-level seroprevalence.METHODS We measured the kinetics of early antibody responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in a cohort of 259 symptomatic North American patients infected with SARS-CoV-2 (up to 75 days after symptom onset) compared to antibody levels in 1548 individuals whose blood samples were obtained prior to the pandemic.RESULTS Between 14-28 days from onset of symptoms, IgG, IgA, or IgM antibody responses to RBD were all accurate in identifying recently infected individuals, with 100% specificity and a sensitivity of 97%, 91%, and 81% respectively. Although the estimated median time to becoming seropositive was similar across isotypes, IgA and IgM antibodies against RBD were short-lived with most individuals estimated to become seronegative again by 51 and 47 days after symptom onset, respectively. IgG antibodies against RBD lasted longer and persisted through 75 days post-symptoms. IgG antibodies to SARS-CoV-2 RBD were highly correlated with neutralizing antibodies targeting the S protein. No cross-reactivity of the SARS-CoV-2 RBD-targeted antibodies was observed with several known circulating coronaviruses, HKU1, OC 229 E, OC43, and NL63.CONCLUSIONS Among symptomatic SARS-CoV-2 cases, RBD-targeted antibodies can be indicative of previous and recent infection. IgG antibodies are correlated with neutralizing antibodies and are possibly a correlate of protective immunity.Competing Interest StatementJAB has been a consultant for T2 Biosystems, DiaSorin and Roche DiagnosticsClinical Protocols https://www.protocols.io/view/sars-cov-2-rbd-elisa-bikbkcsn Funding StatementThis work was supported in part by Centers for Disease Control and Prevention (U01CK000490 to E.T.R, R.C.L., R.C.C, J.B.H, G.M., E.O., S.E.T.), the National Institutes of Health (R01 AI146779 to A.G.S; T32 GM007753 to B.M.H and T.M.C.; T32 AI007245 to J.F) and MassCPR grant to A.G.S.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All research was approved by the Institutional Review Board for Human Subjects Research at Massachusetts General Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe plan to make the data available on Zenodo and at the GitHub repository with the link below after publication. https://github.com/fjones2222/covid19-serodynamics